Embla Medical hf 관리

관리 기준 확인 3/4

Embla Medical hf CEO는 Sveinn Solvason, Apr2022 에 임명되었습니다 의 임기는 2.58 년입니다. 총 연간 보상은 $ 1.18M, 48.8% 로 구성됩니다. 48.8% 급여 및 51.2% 보너스(회사 주식 및 옵션 포함). 는 DKK 2.45M 가치에 해당하는 회사 주식의 0.016% 직접 소유합니다. 2.45M. 경영진과 이사회의 평균 재임 기간은 각각 2.6 년과 15.8 년입니다.

주요 정보

Sveinn Solvason

최고 경영자

US$1.2m

총 보상

CEO 급여 비율	48.8%
CEO 임기	2.6yrs
CEO 소유권	0.02%
경영진 평균 재임 기간	2.6yrs
이사회 평균 재임 기간	15.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Sveinn Solvason 의 보수는 Embla Medical hf 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	US$69m
Jun 30 2024	n/a	n/a	US$61m
Mar 31 2024	n/a	n/a	US$57m
Dec 31 2023	US$1m	US$576k	US$58m
Sep 30 2023	n/a	n/a	US$52m
Jun 30 2023	n/a	n/a	US$45m
Mar 31 2023	n/a	n/a	US$43m
Dec 31 2022	US$780k	US$409k	US$43m

보상 대 시장: Sveinn 의 총 보상 ($USD 1.18M ) UK 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 2.07M ).

보상과 수익: Sveinn 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Sveinn Solvason (46 yo)

2.6yrs

테뉴어

US$1,180,000

보상

Mr. Sveinn Solvason had been Chief Financial Officer of Embla Medical hf. (formerly known as ssur hf.) since May 2013 until April 1, 2022 and serves as its President & CEO since April 1, 2022.Mr. Solvaso...

리더십 팀

이름	위치	테뉴어	보상	소유권
Sveinn Solvason	President & CEO	2.6yrs	US$1.18m	0.016% DKK 2.5m
Ossur Kristinsson	Founder	no data	US$25.00k	데이터 없음
Gudny Sveinsdottir	Chief Financial Officer	2.2yrs	데이터 없음	데이터 없음
Lukas Marklin	Chief Operating Officer	1.4yrs	데이터 없음	데이터 없음
Edda Luovigsdottir	Investor Relations Director	no data	데이터 없음	데이터 없음
Margret Fridriksdottir	Executive Vice President of People	no data	US$242.00k	0.0083% DKK 1.3m
Olafur Gylfason	Chief Commercial Officer	no data	US$600.00k	0.0030% DKK 459.8k
Gudjon Karason	Executive Vice President of EMEA & APAC	7yrs	데이터 없음	0.023% DKK 3.5m
Christian Robinson	President of Americas	no data	데이터 없음	0.0031% DKK 473.6k
Hildur Einarsdottir	Executive Vice President of Research & Development	2.6yrs	데이터 없음	0.00014% DKK 21.5k

2.6yrs

평균 재임 기간

50yo

평균 연령

경험이 풍부한 관리: 0FIW 의 관리팀은 경험 ( 2.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Niels Jacobsen	Chairman of the Board	19.8yrs	US$108.00k	0.048% DKK 7.3m
Svafa Gronfeldt	Vice Chairman of the Board	16.8yrs	US$72.00k	데이터 없음
Gudbjorg Eggertsdottir	Independent Director	11.7yrs	US$43.00k	0.0062% DKK 944.1k
Arne Nielsen	Director	15.8yrs	US$50.00k	데이터 없음
Alberto Esquenazi	Independent Director	3.7yrs	US$43.00k	데이터 없음

15.8yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: 0FIW 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 15.8 년).

Embla Medical hf 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Össur hf. Appoints Caroline Vagner Rosenstand to the Audit Committee

Less than half of directors are independent

Recent updates

Investor sentiment improves as stock rises 18%

Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.033 in 3Q 2023)

Less than half of directors are independent

Less than half of directors are independent

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Less than half of directors are independent

First quarter 2024 earnings released: EPS: US$0.019 (vs US$0.024 in 1Q 2023)

Less than half of directors are independent

Össur hf. Appoints Caroline Vagner Rosenstand to the Audit Committee

Less than half of directors are independent

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: US$0.14 (vs US$0.10 in FY 2022)

Össur hf. Provides Earnings Guidance for the Year 2024

Less than half of directors are independent

Össur hf. to Report Q1, 2024 Results on Apr 23, 2024

Össur hf., Annual General Meeting, Mar 12, 2025

Less than half of directors are independent

Össur hf. Reaffirms Financial Guidance for the Year 2023

Less than half of directors are independent

Össur hf. Announces Executive Changes

First quarter 2023 earnings released: EPS: US$0.024 (vs US$0.022 in 1Q 2022)

Less than half of directors are independent

Less than half of directors are independent

Össur hf. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Less than half of directors are independent

Össur hf. to Report Q1, 2023 Results on Apr 25, 2023

Less than half of directors are independent

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: US$0.016 (vs US$0.041 in 3Q 2021)

Less than half of directors are independent

Össur hf. (CPSE:OSSR) acquired Naked Prosthetics.

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: US$0.034 (vs US$0.046 in 2Q 2021)

Össur hf. Revises Earnings Guidance for the Year 2022

Össur hf. Reports Preliminary Earnings Results for the Second Quarter and First Half of 2022

Less than half of directors are independent

Össur Appoints Gudny Arna Sveinsdottir as Chief Financial Officer, Effective September 1, 2022

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Össur Hf. Announces New R&D Leadership

Less than half of directors are independent

Össur Launches New POWER KNEE

Össur hf. Announces Sales Guidance for the Full Year 2022

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Össur Hf. Announces Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS US$0.027 (vs US$0.017 in 1Q 2020)

Össur Hf. Provides Financial Guidance for the Full Year 2021

Vice Chairman Kristján Ragnarsson has left the company

Full year 2020 earnings released: EPS US$0.015 (vs US$0.16 in FY 2019)

Revenue misses expectations

Össur hf., Annual General Meeting, Mar 08, 2022

Laboratoires Innothera S.A.S completed the acquisition of Gibaud SAS from Össur hf. (CPSE:OSSR).

Össur Hf. Withdraw Its Financial Guidance for 2020

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령